دورية أكاديمية
Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study
| العنوان: | Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study |
|---|---|
| المؤلفون: | Nahla Mohamed Teama, Waleed Anwar Abdel-Mohsen, Ossama Ashraf Ahmed, Sarah Mohamed El Sayed, Ahmed Mohamed ElGhandour |
| المصدر: | Egyptian Liver Journal, Vol 11, Iss 1, Pp 1-8 (2021) |
| بيانات النشر: | SpringerOpen, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Surgery LCC:Diseases of the digestive system. Gastroenterology |
| مصطلحات موضوعية: | Ombitasvir, Paritaprevir, Ritonavir, Ribavirin chronic hepatitis C, Hemodialysis, Surgery, RD1-811, Diseases of the digestive system. Gastroenterology, RC799-869 |
| الوصف: | Abstract Background Prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population. FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease. This study aimed to evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without ribavirin in treatment of chronic hepatitis C Egyptian hemodialysis patients to compare it with the same treatment result in chronic hepatitis C Egyptian patients with normal renal functions. This case-control study was conducted on one hundred patients with confirmed diagnosis of HCV-positive infection at the Center of National Committee for Control of Viral Hepatitis [NCCVH] at Ain Shams University Hospital. Patients were divided into two groups: group I (control group) with 50 chronic hepatitis C virus patients with normal renal functions and group II (Case Group) with 50 chronic hepatitis C virus hemodialysis patients. Results 95.1% of prevalent hemodialysis patients achieved sustained virological response (SVR), while 100% of patients with normal kidney functions achieved sustained virological response. Most common side effects were hemoglobin drop, gastrointestinal disturbance, severe fatigue, and itching. Conclusion Ombitasvir, paritaprevir, and ritonavir are considered a safe and effective in treatment in HCV infection in patients on regular hemodialysis as in chronic hepatitis C virus infection patients with normal kidney functions. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2090-6226 |
| Relation: | https://doaj.org/toc/2090-6226 |
| DOI: | 10.1186/s43066-021-00079-7 |
| URL الوصول: | https://doaj.org/article/d99beeee59db4148b6bc99c8f55f5e86 |
| رقم الأكسشن: | edsdoj.99beeee59db4148b6bc99c8f55f5e86 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 20906226 |
|---|---|
| DOI: | 10.1186/s43066-021-00079-7 |